Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170788 | 0.98 | IDO1 (0.46) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7115970 | 0.90 | IDO1 (0.44) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL8910008 | 0.81 | CYP19A1 (0.42) | MAPTGAAL3MBTL1EPHX1KDM4E | |
| SCHEMBL959762 | 0.81 | SLC6A3 (0.58) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL13124077 | 0.81 | SLC6A3 (0.58) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL8909681 | 0.80 | CYP11B2 (0.44) | MAPTKDM4EPKMSLC6A3 | |
| SCHEMBL961019 | 0.78 | SLC6A3 (0.57) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL28135586 | 0.76 | IDO1 (0.47) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL961750 | 0.74 | SLC6A3 (0.53) | IDO1MEN1KMT2ALMNAMAPT | |
| SCHEMBL28013782 | 0.74 | IDO1 (0.46) | IDO1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | claimed |
| CN-101052397-B | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD | 2011-07-06 | — | — | CN | claimed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | claimed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | claimed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | claimed |
| CN-101052397-A | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-10 | — | — | CN | claimed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | claimed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | claimed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | claimed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | claimed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| US-6262269-B1 | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | TREGA BIOSCIENCES, INC. | 2001-07-17 | — | — | US | claimed |
| EP-0983507-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0977989-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| WO-1993020061-A1 | 4-[4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993020062-A1 | PROCESS FOR THE PREPARATION OF 4-PYRIDYL- AND 4-PIPERIDINYLIMIDAZOLES USEFUL AS INTERMEDIATES FOR THE SYNTHESIS OF HISTAMINE RECEPTOR ANTAGONISTS | THE UNIVERSITY OF TOLEDO (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | IDO1 808/4885MEN1 4731/4885KMT2A 3454/4885 |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | IDO1 50/4885MEN1 2370/4885KMT2A 2219/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | IDO1 62/4885MEN1 1990/4885KMT2A 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.